Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakesDavid J. Ponting, Robert Thomas, James Harvey et al.|Regulatory Toxicology and Pharmacology|2024Cited by 13
Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines – a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limitsSusan P. Felter, Joel P. Bercu, Yi Yan Yang et al.|Regulatory Toxicology and Pharmacology|2025Cited by 5